FDA Grants Accelerated Approval for Semaglutide in MASH Treatment, but Equity Gaps Persist in Clinical Trials

The FDA granted accelerated approval for semaglutide查看药品详情 as a first-line treatment for adults with moderate to severe metabolic dysfunction-associated steatohepatitis (MASH (搜索)搜索该疾病) in August 2025, marking a significant milestone in liver disease treatment. The decision was based on positive data from an ongoing phase 3 clinical trial, with full approval expected once the trial is complete and additional data is reviewed.

Clinical Trial Results Drive Approval Decision

The FDA's accelerated approval came after early trial results demonstrated substantial efficacy. After 72 weeks, 63 percent of patients receiving semaglutide查看药品详情 resolved their MASH (搜索)搜索该疾病 and didn't experience worse liver scarring or fibrosis, compared with 34 percent of those taking a placebo. Additionally, 37 percent of patients receiving semaglutide improved their liver fibrosis (搜索)搜索该疾病 without their MASH worsening, compared with 22 percent of those taking a placebo.

The ongoing trial is planned to last a total of 240 weeks, at which point the FDA will evaluate whether patients' improvements in liver inflammation and scarring observed after 72 weeks resulted in fewer deaths, liver transplants, and other liver-related health events.

Mechanism of Action in MASH Treatment

Semaglutide查看药品详情 improves MASH (搜索)搜索该疾病 by addressing two of its underlying causes: excess body fat and high blood sugar. Both lead to excess fat accumulation and inflammation in the liver, which can lead to scarring or fibrosis over time.

"By inducing weight loss and improving metabolic health, semaglutide查看药品详情 can decrease toxicity from fat accumulation and liver cell damage, allowing the liver to heal and achieve fibrosis regression," says Naim Alkhouri, MD, hematologist and chief medical officer at Summit Clinical Research in Phoenix.

Treatment Considerations for Different Patient Populations

Patients with Diabetes

The clinical trial exploring semaglutide查看药品详情 as a MASH (搜索)搜索该疾病 treatment is testing a weekly 2.4 milligram dose, the maximum Wegovy查看药品详情 dose, which is slightly higher than the maximum weekly 2 mg dose approved for Ozempic查看药品详情 to treat diabetes (搜索)搜索该疾病. "Patients already on semaglutide for diabetes who want to treat MASH should talk to their provider to see if dose escalation is right for them," says A. Sidney Barritt IV, MD, director of hepatology at UNC School of Medicine in Chapel Hill, North Carolina.

Patients Without Obesity

Not everyone with MASH (搜索)搜索该疾病 has obesity (搜索)搜索该疾病, and semaglutide查看药品详情 may not be as effective for these patients. "[Because] the semaglutide benefit is mostly indirect through control of weight and diabetes (搜索)搜索该疾病, patients without these comorbidities may not receive the same benefits," says Dr. Barritt. For these patients, alternative treatments like resmetirom查看药品详情 may be worth considering.

Pediatric Patients

While semaglutide查看药品详情 is approved to treat obesity (搜索)搜索该疾病 in children over 12 years old, it's not currently approved to treat MASH (搜索)搜索该疾病 in those under 18. MASH may be surprisingly common among children and teens, but treatment options remain limited to dietary changes and other lifestyle modifications.

Equity Gaps in Clinical Trial Representation

Despite the promising results, new research reveals significant representation gaps in GLP-1 weight loss trials. A systematic review of 149 clinical trials presented at The Liver Meeting found that Black and Hispanic individuals were substantially underrepresented compared to obesity (搜索)搜索该疾病 prevalence in these populations.

"As semaglutide查看药品详情 and other GLP-1 receptor (搜索)搜索该靶点 agonists gain new indications, trial design and health system strategies must prioritize equity to ensure that the transformative benefits of these therapies reach populations who need them most," said Kimberly Ho, MD, internal medicine resident at The Warren Alpert Medical School of Brown University.

The analysis of 24 studies comprising 16,600 participants revealed that white participants were overrepresented, making up 69% of participants in all trials and 75% of U.S. trials. Although 50% of Black adults in the U.S. have obesity (搜索)搜索该疾病, Black participants made up just 6% of U.S. trials. Hispanic patients were also underrepresented, comprising 27% of participants in U.S. trials despite obesity prevalence of 45%.

Limited MASLD/MASH Representation in Trials

The research also found that patients with MASLD (搜索)搜索该疾病 and MASH (搜索)搜索该疾病 were underrepresented in trials. Although the prevalence of MASLD or MASH reaches about 40% in the U.S., only 18% of participants in trials had these conditions. The proportion was even lower in U.S.-based studies, where only 8% of participants had MASLD or MASH, compared with 26% of those in international studies.

Safety Considerations and Contraindications

Semaglutide查看药品详情 carries specific contraindications and may not be appropriate for all patients. The medication should not be used by individuals with a personal or family history of medullary thyroid cancer, gastroparesis, multiple endocrine neoplasia type 2, or type 1 diabetes (搜索)搜索该疾病. Pregnant or breastfeeding women should also avoid the medication.

For patients with severe liver disease complications like cirrhosis (搜索)搜索该疾病, semaglutide查看药品详情's safety remains unclear. Some research suggests that rapid weight loss caused by semaglutide could potentially worsen liver scarring, though the mechanism is not yet understood.

Current Approval Scope

At present, semaglutide查看药品详情 is only approved to treat MASH (搜索)搜索该疾病, not the milder form known as metabolic dysfunction-associated liver disease (MASLD (搜索)搜索该疾病). However, since weight loss is a cornerstone of MASLD treatment, doctors may recommend semaglutide for overweight or obese patients with MASLD to reach a healthier weight and potentially improve liver health.

The medication is not considered effective for advanced liver complications and isn't currently recommended for patients with cirrhosis (搜索)搜索该疾病 or liver failure.